Investigational drug · Phase 3
MG-K10 Humanized Monoclonal Antibody
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Seasonal Allergic Rhinitis, Chronic Spontaneous Urticaria (CSU).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
22
Any phase or sponsor naming "MG-K10 Humanized Monoclonal Antibody"
First trial start
2025
Mar 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MG-K10 Humanized Monoclonal Antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Seasonal Allergic Rhinitis
- Chronic Spontaneous Urticaria (CSU)
- Atopic Eczema
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Chronic hives (urticaria) · Allergies (allergic rhinitis) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "MG-K10 Humanized Monoclonal Antibody" as an intervention, largest first.
- Study of Adjuvant ONO-4538 With Resected Gastric CancerPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT03006705 · 800 participants · Start Jan 31, 2017 · Primary completion Aug 17, 2022
Drug: Nivolumab; Tegafur-gimeracil-oteracil potassium and 3 more · For: Gastric Cancer
Sites: Anhui Province, China; Beijing, China; Cuangdong Province, China · 108 sites in all
- Study of ONO-4538 in Gastric CancerPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT02746796 · 680 participants (planned) · Start Mar 2016 · Primary completion Jan 2020
Drug: ONO-4538; Oxaliplatin and 3 more · For: Gastric Cancer
Sites: Nagoya, Japan; Hirosaki, Japan; Misawa, Japan · 130 sites in all
- Clinical Trial of MG-K10 in Stage III of Moderate to Severe AsthmaPivotal-lookingRecruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT06837922 · 504 participants (planned) · Start Mar 25, 2025 · Primary completion Nov 15, 2027
Drug: MG-K10/Placebo · For: Asthma
Sites: Guangzhou, China
- A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic DermatitisPivotal-lookingNot yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07479615 · 498 participants (planned) · Start May 1, 2026 · Primary completion Jan 2029
Drug: MG-K10 Humanized Monoclonal Antibody Injection · For: Atopic Dermatitis; Atopic Eczema
- Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic DermatitisPivotal-lookingStatus unknown
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT06026891 · 498 participants (planned) · Start Jan 13, 2024 · Primary completion Jun 11, 2025
Drug: MG-K10/Placebo · For: Atopic Dermatitis
Sites: Beijing, China
- A Study of MG-K10 in Chronic Spontaneous UrticariaPivotal-lookingNot yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07546487 · 226 participants (planned) · Start Apr 14, 2026 · Primary completion Mar 31, 2028
Drug: MG-K10 Humanized Monoclonal Antibody Injection; Placebo · For: Chronic Spontaneous Urticaria (CSU)
- A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal PolypsPivotal-lookingNot yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07903194 · 210 participants (planned) · Start Oct 27, 2026 · Primary completion Dec 21, 2027
Drug: MG-K10; Placebo and 1 more · For: Chronic Rhinosinusitis With Nasal Polyps
- A Study of MG-K10 in Subjects With AsthmaPivotal-lookingStatus unknown
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT05382910 · 180 participants (planned) · Start Jul 5, 2022 · Primary completion Dec 20, 2023
Drug: MG-K10; Placebo · For: Asthma
Sites: Guangzhou, China
- A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07540442 · 180 participants (planned) · Start Apr 17, 2026 · Primary completion Jan 5, 2027
Drug: MG-K10 Injection (Humanized Monoclonal Antibody); Placebo for MG-K10 · For: Dermatitis, Atopic
Sites: Shenyang, China
- A Study of MG-K10 in Subjects With Atopic DermatitisPivotal-lookingStatus unknown
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT05466877 · 163 participants (planned) · Start Aug 31, 2022 · Primary completion Sep 22, 2023
Drug: MG-K10; Placebo · For: Atopic Dermatitis
Sites: Bengbu, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.